preferred anti angiogenesis agents include sunitinib sutenttm bevacizumab (Pfizer Inc)
86
Structured Review
Pfizer Inc
preferred anti angiogenesis agents include sunitinib sutenttm bevacizumab
Preferred Anti Angiogenesis Agents Include Sunitinib Sutenttm Bevacizumab, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sutenttm/anti+avelumab/us12447153-758-0-13
Average 86 stars, based on 1 article reviews
Preferred Anti Angiogenesis Agents Include Sunitinib Sutenttm Bevacizumab, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sutenttm/anti+avelumab/us12447153-758-0-13
Average 86 stars, based on 1 article reviews
preferred anti angiogenesis agents include sunitinib sutenttm bevacizumab - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Comparison:Article Title: Investigational drugs for neuroendocrine tumours. Article Snippet: Background: Neuroendocrine tumours (NETs) are usually slow-growing neoplasms, which arise in the gastrointestinal tract, endocrine pancreas, lungs or thymus.. The majority are malignant.. The treatment of patients with metastatic disease consists of biotherapy with alpha-interferon and somatostatin analogues, various chemotherapy combinations or liver embolization. Article Title: Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer Article Snippet: Primary tumor tissue (the “sunitinib set”) was collected and snap frozen from mccRCC patients treated with three cycles of Article Title: The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Article Snippet: This paper examines the challenge of conducting economic evaluations to support patient access to cancer therapies when the cost-effectiveness estimation is hampered by cross- Article Title: Posterior reversible encephalopathy syndrome during sunitinib therapy. Article Snippet: r é s u m é Un cas d’encéphalopathie postérieure réversible survenu au cours de l’administration de sunitinib dans le cadre du traitement d’un carcinome rénal à cellules claires métastasé est décrit.. Il s’agit du troisième cas décrit dans la littérature.. Les trois cas sont très similaires sauf pour la durée d’exposition au sunitrinib, de huit jours à cinq mois. Methylation:Article Title: Investigational drugs for neuroendocrine tumours. Article Snippet: Background: Neuroendocrine tumours (NETs) are usually slow-growing neoplasms, which arise in the gastrointestinal tract, endocrine pancreas, lungs or thymus.. The majority are malignant.. The treatment of patients with metastatic disease consists of biotherapy with alpha-interferon and somatostatin analogues, various chemotherapy combinations or liver embolization. Article Title: Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer Article Snippet: Primary tumor tissue (the “sunitinib set”) was collected and snap frozen from mccRCC patients treated with three cycles of Article Title: The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Article Snippet: This paper examines the challenge of conducting economic evaluations to support patient access to cancer therapies when the cost-effectiveness estimation is hampered by cross- Article Title: Posterior reversible encephalopathy syndrome during sunitinib therapy. Article Snippet: r é s u m é Un cas d’encéphalopathie postérieure réversible survenu au cours de l’administration de sunitinib dans le cadre du traitement d’un carcinome rénal à cellules claires métastasé est décrit.. Il s’agit du troisième cas décrit dans la littérature.. Les trois cas sont très similaires sauf pour la durée d’exposition au sunitrinib, de huit jours à cinq mois. |